Alpha-gal epitope-expressing tumor cell

Alpha-gal epitope-expressing tumor cell refers to a tumor cell that has been genetically or enzymatically modified to present the carbohydrate antigen α-Gal (Galα1-3Galβ1-4GlcNAc-R) on its surface, a structure not found naturally on human cells but abundant in non-primate mammals due to the action of α1,3-galactosyltransferase. Such modification exploits the high abundance of natural anti-Gal antibodies in humans, leading to robust opsonization of the engineered tumor cells. Upon opsonization, these cells are efficiently phagocytosed by macrophages and dendritic cells, which in turn process and present tumor-associated antigens to T cells, initiating a potent anti-tumor immune response. This approach has been investigated as a method to convert poorly immunogenic autologous tumor cells into effective vaccines, significantly enhancing immunogenicity and providing protection in preclinical cancer models[1][3][4][5][6]. Safety concerns relate to the potential for exaggerated immune responses as well as allergic phenomena involving anti-Gal antibodies[7].

Other names

Tumor cell expressing α-Gal epitopeα-Gal-expressing tumor cellGalα1-3Galβ1-4GlcNAc-R-expressing tumor cell

Opsonization by anti-Gal antibodies, promoting rapid uptake/destruction of tumor cells by APCs (macrophages, dendritic cells)[1][3][4][5]. APCs process and present tumor-associated antigens from these tumor cells, activating adaptive immune responses, notably CD8+ T cells[1][3][6].